Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Jaguar Health Inc

JAGX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$0.92

▲ +16.97%

Market Cap $4.50M · Vol 105.71K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.50M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

43.64

Momentum

Beta

-0.04

vs Market

52W High

$84.35

98.91% below

52W Low

$0.75

22.62% above

Volume

105.71K

Avg 16.11K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

91.42%

Public shares

Shariah Compliance8 STANDARDS

✗ Jaguar Health Inc (JAGX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does JAGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.13%

-57.79%

-76.75%

-95.86%

YTD

-97.19%

-98.74%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$11.51M
Net Income	$-53,997,000.00
Revenue Growth (YoY)	+815.63%
Gross Margin	67.21%
Operating Margin	-391.87%
Net Profit Margin	-469.09%
ROE	N/A
ROA · ROIC	-117.71% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.19
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	4.91M

Technical Indicators

50-Day SMA	$1.92
200-Day SMA	$20.45
RSI (14)	43.64
Beta	-0.04
52-Week High	$84.35
52-Week Low	$0.75

Volume Today	105.71K
Avg Daily Volume (30D)	16.11K
Relative Volume	6.56x
Volatility (10D)	124.30
Volatility (30D)	155.12
Free Float	91.42%

Analyst Consensus

N/A

Current Price $0.92

Mean Target N/A

52W Low$0.75 52W High$84.35

Current

Target

$0.75 $84.35

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG005Z205T2

ISINUS47010C8626

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateMar 31, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.